Details checkedClinical trial listing onlyCheckedregistry

Fudan huperzine A presbycusis/tinnitus study

Also known as: BTHE and Huperzine A, Huperzine A presbycusis study, NCT03101722

Institution-led study

Primary source

Sponsor / Institution

Institution-led study

Program Type

Therapeutic

Modality

Small Molecule

Stage

Interventional/NA

Status

Active

Target Gene

—

Route / Mode

Oral tablet/capsule plus basic treatment and health education

Confidence

82%

Status Confidence

Status needs checking

Evidence Strength

Needs more support

Last Reviewed

2026-06-09

Geography

China

Population

older-adult, age-related, tinnitus, sensorineural

Trial IDs

Mechanism

Active invitation-only randomized study testing oral huperzine A plus basic treatment and health education for hearing-function protection, tinnitus suppression, and cognitive outcomes in older adults with presbycusis-related tinnitus.

Indications

Hearing Loss Sensorineural Hearing Loss Age-Related Hearing Loss Tinnitus

Notes

Normalized from an intervention-arm label into the Fudan investigator-led huperzine A study. ClinicalTrials.gov lists the study as enrolling by invitation; no company sponsor or commercial program was verified in this pass.

Evidence & Sources

1 structured sources

clinicaltrials

Supports: canonicalName, aliases, allCompanies, isIndustrySponsored, stage, status, route, indications...

IDs: NCT03101722

Open

Key Events

2017-05-15

Fudan huperzine A presbycusis/tinnitus study started

2024-10-01

ClinicalTrials.gov posted latest enrolling-by-invitation update reviewed in this pass

Clinical Trials (1)